Fenspiride
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pharmacological action - bronchodilatory, anti-inflammatory.
Pharmacodynamics
Anti-inflammatory and anti-bronchoconstrictor activity of fenspiride is due to a decrease in the production of a number of biologically active substances (cytokines, especially TNF-α, arachidonic acid derivatives, free radicals), which play an important role in the development of inflammation and bronchospasm.
H has1- an antihistamine effect, reduces the effect of a number of factors that contribute to the hypersecretion of pro-inflammatory factors, the development of inflammation and bronchial obstruction. Fenspirid also has a spasmolytic effect.
Pharmacokinetics
After ingestion Tmax drug in blood plasma - 6 h. T1/2 The drug is 12 hours. Excreted mainly by the kidneys.
Indications
Diseases of the upper and lower respiratory tract:
- rhinopharyngitis and laryngitis;
- tracheobronchitis;
- bronchitis (with or without chronic respiratory failure);
- bronchial asthma (as part of complex therapy);
- respiratory symptoms (cough, hoarseness, sore throat) for measles, whooping cough and flu;
- infectious diseases of the respiratory tract, accompanied by cough, when shown standard antibiotic therapy;
- otitis media and sinusitis of various etiologies.
Composition
pills of prolonged action, film-coated white or almost white color, round, biconvex; on the cross-section - the core is white or almost white.
1 tab. | |
fenspiride hydrochloride | 80 mg |
Excipients: Kollidon SR (polyvinyl acetate 80%, povidone 19%, sodium lauryl sulfate 0.8%, silicon dioxide 0.2%) - 120 mg, calcium hydrogen phosphate dihydrate - 95.5 mg, silicon colloid dioxide - 1.5 mg, magnesium stearate - 3 mg.
The composition of the film coating: hypromellose - 4.5 mg, talc - 1.764 mg, hyprolosis (hydroxypropylcellulose) - 1.746 mg, titanium dioxide - 0.99 mg or dry mixture for film coating containing hypromellose (50%), hyprolose (hydroxypropylcellulose) (19.4%), talc (19.6%), titanium dioxide (11%) - 0.99 mg.
Fenspiride is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
ELADON | Vertex | Russia | pills |
Syresp® | Medana Pharma | Poland | syrup |
No customer reviews for the moment.
Dosage and Administration
For oral use
Adults: 1 tab. 2-3 times a day. The maximum daily dose is 240 mg. The duration of treatment is determined by the doctor.
Adverse reactions
The frequency of side effects that may occur during therapy is given in the following grades: very often - ≥1 / 10 (≥10%); often from ≥1 / 100 to
From the CCC: rarely - moderate tachycardia, the severity of which decreases with a decrease in the dose of the drug.
From the digestive system: often - gastrointestinal disorders, nausea, epigastric pain; Unspecified frequency - diarrhea, vomiting.
From the side of the central nervous system: rarely - drowsiness; Unspecified frequency - dizziness.
On the part of the skin: rarely - erythema, rash, urticaria, angioedema, fixed erythema pigmentosa; Unassigned frequency - pruritus.
Other: Unknown frequency - asthenia, increased fatigue.
Contraindications
- Hypersensitivity to the active substance and / or any of the components of the drug;
- age up to 18 years.
Drug interactions
Special studies on the interaction of fenspiride with other drugs have been conducted.
Because of the possible increase in sedation when taking histamine H blockers1-receptors do not recommend the use of the drug Eladon® in combination with drugs that have a sedative effect, or in conjunction with alcohol.
Pregnancy and Lactation
Taking the drug during pregnancy is not recommended.
Fenspiride therapy is not a reason to terminate the onset of pregnancy. There are no clinical data on the fetotoxic effect of fenspiride or its ability to cause malformations when taken during pregnancy.
Do not use Eladon® during the breastfeeding period due to the lack of data on the penetration of fenspiride into breast milk.
Special instructions
Impact on the ability to drive and work with mechanisms. Studies on the effect of the drug Eladon® the ability to drive vehicles and work with mechanisms were not carried out. Patients should be aware of the possible development of drowsiness while taking Eladon®, especially at the beginning of therapy or in combination with alcohol intake, and should be careful when driving vehicles and performing work that requires a high speed of psychomotor reactions.
Overdosage
In case of overdose of the drug (there are cases of overdose when taking the drug in a dose of more than 2320 mg) should immediately seek medical help.
Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.
Treatment: gastric lavage, ECG monitoring. Maintaining vital body functions.
- Brand name: ELADON
- Active ingredient: Fenspirid
- Dosage form: Pills: round, biconvex, film-coated white or almost white. In cross section, the core is white or almost white.
- Manufacturer: Vertex
- Country of Origin: Russia
Studies and clinical trials of Fenspiride (Click to expand)
- The determination of fenspiride in human plasma and urine by liquid chromatography with electrochemical or ultraviolet detection
- Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial
- Inhibition of the development of myringosclerosis by local administration of fenspiride, an anti-inflammatory drug
- Contre-indication chez l’enfant de moins de deux ans des médicaments antitussifs antihistaminiques H1 de première génération et du fenspiride utilisés dans le traitement de la toux
- Effect of Fenspiride, a Non-steroidal Antiinflammatory Agent, on Neurogenic Mucus Secretion in Ferret Trachea in Vitro
- Fenspiride interferes with neutrophil migration into the peritoneal cavity induced by endotoxln and activated zymosan
- Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat
- Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia
- PRS7 COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND
- Fenspiride and membrane transduction signals in rat alveolar macrophages
- Fenspiride inhibits histamine-induced responses in a lung epithelial cell line
- Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis
- Comparison of Fenspiride with Beclomethasone as Adjunctive Anti-Inflammatory Treatment in Patients with Chronic Obstructive Pulmonary Disease
- Concomitant fenspiride worthwhile in chronic bronchitis
- Protective Effect of Fenspiride on the Bronchi in Rats with Chronic Obstructive Pulmonary Disease
- Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Functional and biochemical study
- Fenspiride prevents LPS-induced lethal effect in mice
- Concomitant fenspiride worthwhile in chronic bronchitis
- Large-volume injection of sample diluents not miscible with the mobile phase as an alternative approach in sample preparation for bioanalysis: an application for fenspiride bioequivalence
- Some Aspects of Quality Risk Management for the Fenspiride Hydrochloride (0.08 G Coated Tablets) Production Process at the Pharmaceutical Development Stage
- Effect of Fenspiride on Pulmonary Function in the Rat and Guinea Pig
- Recherche de stupéfiant par bandelettes urinaires – suspicion de réaction croisée entre fentanyl et fenspiride
- New Approach for Determination of the Degradation Products of Fenspiride Hydrochloride Found in Oral Liquid Formulations